Signaling revealed by mapping molecular interactions: Implications for ErbB-targeted cancer immunotherapies

G. Vereb, Péter Nagy, John W. Park, J. Szöllősi

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The ErbB2 (HER2) protein is a member of the EGF receptor (ErbB) family of transmembrane receptor tyrosine kinases. Although no direct ligand has yet been assigned to ErbB2, recent biochemical and biophysical evidence suggests that this protein operates as a shared receptor subunit with other ErbB proteins. Its medical importance stems form its frequent overexpression in breast and other cancers, resulting in various tumorigenic phenotypic changes, including higher transforming activity, metastatic potential, angiogenesis and drug resistance. The multitude of possible small-scale and large-scale interactions among the ErbB proteins makes them especially diverse and important in initiating and directing signal transduction. The mechanisms of homo- and hetero-associations among ErbB proteins in the cell membrane in relation to signal transduction events remain a critical focus of investigation. Recent studies to map the molecular interactions involved in the ErbB signaling network are elucidating these mechanisms, and promise to facilitate the development of new ErbB-targeted therapies, including approaches using antibodies, immunoliposomes, cancer vaccines, gene therapy and small molecule inhibitors.

Original languageEnglish
Pages (from-to)169-186
Number of pages18
JournalClinical and Applied Immunology Reviews
Volume2
Issue number3
DOIs
Publication statusPublished - Jun 2002

Fingerprint

Immunotherapy
Signal Transduction
Neoplasms
Proteins
Active Immunotherapy
Cancer Vaccines
Neoplasm Genes
Receptor Protein-Tyrosine Kinases
Epidermal Growth Factor Receptor
Drug Resistance
Genetic Therapy
Membrane Proteins
Breast Neoplasms
Ligands
Antibodies
Therapeutics

Keywords

  • Breast cancer
  • ErbB family
  • Fluorescence resonance energy transfer
  • Herceptin®
  • Immunoliposomes
  • Lipid rafts
  • Receptor tyrosine kinases
  • Scanning nearfield optical microscopy
  • Trastuzumab

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Immunology and Allergy
  • Infectious Diseases

Cite this

Signaling revealed by mapping molecular interactions : Implications for ErbB-targeted cancer immunotherapies. / Vereb, G.; Nagy, Péter; Park, John W.; Szöllősi, J.

In: Clinical and Applied Immunology Reviews, Vol. 2, No. 3, 06.2002, p. 169-186.

Research output: Contribution to journalArticle

@article{0258f2bbe8884620bd246f9113bfbae2,
title = "Signaling revealed by mapping molecular interactions: Implications for ErbB-targeted cancer immunotherapies",
abstract = "The ErbB2 (HER2) protein is a member of the EGF receptor (ErbB) family of transmembrane receptor tyrosine kinases. Although no direct ligand has yet been assigned to ErbB2, recent biochemical and biophysical evidence suggests that this protein operates as a shared receptor subunit with other ErbB proteins. Its medical importance stems form its frequent overexpression in breast and other cancers, resulting in various tumorigenic phenotypic changes, including higher transforming activity, metastatic potential, angiogenesis and drug resistance. The multitude of possible small-scale and large-scale interactions among the ErbB proteins makes them especially diverse and important in initiating and directing signal transduction. The mechanisms of homo- and hetero-associations among ErbB proteins in the cell membrane in relation to signal transduction events remain a critical focus of investigation. Recent studies to map the molecular interactions involved in the ErbB signaling network are elucidating these mechanisms, and promise to facilitate the development of new ErbB-targeted therapies, including approaches using antibodies, immunoliposomes, cancer vaccines, gene therapy and small molecule inhibitors.",
keywords = "Breast cancer, ErbB family, Fluorescence resonance energy transfer, Herceptin{\circledR}, Immunoliposomes, Lipid rafts, Receptor tyrosine kinases, Scanning nearfield optical microscopy, Trastuzumab",
author = "G. Vereb and P{\'e}ter Nagy and Park, {John W.} and J. Sz{\"o}llősi",
year = "2002",
month = "6",
doi = "10.1016/S1529-1049(02)00044-2",
language = "English",
volume = "2",
pages = "169--186",
journal = "Clinical and Applied Immunology Reviews",
issn = "1529-1049",
publisher = "Elsevier BV",
number = "3",

}

TY - JOUR

T1 - Signaling revealed by mapping molecular interactions

T2 - Implications for ErbB-targeted cancer immunotherapies

AU - Vereb, G.

AU - Nagy, Péter

AU - Park, John W.

AU - Szöllősi, J.

PY - 2002/6

Y1 - 2002/6

N2 - The ErbB2 (HER2) protein is a member of the EGF receptor (ErbB) family of transmembrane receptor tyrosine kinases. Although no direct ligand has yet been assigned to ErbB2, recent biochemical and biophysical evidence suggests that this protein operates as a shared receptor subunit with other ErbB proteins. Its medical importance stems form its frequent overexpression in breast and other cancers, resulting in various tumorigenic phenotypic changes, including higher transforming activity, metastatic potential, angiogenesis and drug resistance. The multitude of possible small-scale and large-scale interactions among the ErbB proteins makes them especially diverse and important in initiating and directing signal transduction. The mechanisms of homo- and hetero-associations among ErbB proteins in the cell membrane in relation to signal transduction events remain a critical focus of investigation. Recent studies to map the molecular interactions involved in the ErbB signaling network are elucidating these mechanisms, and promise to facilitate the development of new ErbB-targeted therapies, including approaches using antibodies, immunoliposomes, cancer vaccines, gene therapy and small molecule inhibitors.

AB - The ErbB2 (HER2) protein is a member of the EGF receptor (ErbB) family of transmembrane receptor tyrosine kinases. Although no direct ligand has yet been assigned to ErbB2, recent biochemical and biophysical evidence suggests that this protein operates as a shared receptor subunit with other ErbB proteins. Its medical importance stems form its frequent overexpression in breast and other cancers, resulting in various tumorigenic phenotypic changes, including higher transforming activity, metastatic potential, angiogenesis and drug resistance. The multitude of possible small-scale and large-scale interactions among the ErbB proteins makes them especially diverse and important in initiating and directing signal transduction. The mechanisms of homo- and hetero-associations among ErbB proteins in the cell membrane in relation to signal transduction events remain a critical focus of investigation. Recent studies to map the molecular interactions involved in the ErbB signaling network are elucidating these mechanisms, and promise to facilitate the development of new ErbB-targeted therapies, including approaches using antibodies, immunoliposomes, cancer vaccines, gene therapy and small molecule inhibitors.

KW - Breast cancer

KW - ErbB family

KW - Fluorescence resonance energy transfer

KW - Herceptin®

KW - Immunoliposomes

KW - Lipid rafts

KW - Receptor tyrosine kinases

KW - Scanning nearfield optical microscopy

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=0036625779&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036625779&partnerID=8YFLogxK

U2 - 10.1016/S1529-1049(02)00044-2

DO - 10.1016/S1529-1049(02)00044-2

M3 - Article

AN - SCOPUS:0036625779

VL - 2

SP - 169

EP - 186

JO - Clinical and Applied Immunology Reviews

JF - Clinical and Applied Immunology Reviews

SN - 1529-1049

IS - 3

ER -